Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial

BACKGROUND: Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial that randomized 9776 women for the use of hormonal therapy. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Gunda, Aparna, Kranenbarg, Elma Meershoek-Klein, Liefers, Gerrit-Jan, Savitha, Badada Ananthamurthy, Shrivastava, Payal, Serkad, Chandra Prakash Vijay Kumar, Kaur, Taranjot, Eshwaraiah, Mallikarjuna Siraganahalli, Tollenaar, Rob A. E. M., van de Velde, Cornelis J. H., Seynaeve, Caroline M. J., Bakre, Manjiri, Kuppen, Peter J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103430/
https://www.ncbi.nlm.nih.gov/pubmed/37060036
http://dx.doi.org/10.1186/s13058-023-01643-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103430/
https://www.ncbi.nlm.nih.gov/pubmed/37060036
http://dx.doi.org/10.1186/s13058-023-01643-2

Ejemplares similares